Authors

Document Type

Article

Publication Date

4-19-2021

Comments

This article is the author’s final published version in Frontiers in Human Neuroscience, Volume 15, April 2021, Article number 644593

The published version is available at https://doi.org/10.3389/fnhum.2021.644593. Copyright © Vedam-Mai et al.


Corrigendum: Wei Hu was not included as an author in the published article. In the original article, we neglected to include the funders NPF and Tyler’s Hope to Wei Hu. In the original article, there was an error. A donation was omitted. A correction has been made to the Conflict of Interest Statement, with the following sentence added: “Research devices for Dr. Goodman’s NIH funded study were donated by Medtronic.” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Abstract

We estimate that 208,000 deep brain stimulation (DBS) devices have been implanted to address neurological and neuropsychiatric disorders worldwide. DBS Think Tank presenters pooled data and determined that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. The DBS Think Tank was founded in 2012 providing a space where clinicians, engineers, researchers from industry and academia discuss current and emerging DBS technologies and logistical and ethical issues facing the field. The emphasis is on cutting edge research and collaboration aimed to advance the DBS field. The Eighth Annual DBS Think Tank was held virtually on September 1 and 2, 2020 (Zoom Video Communications) due to restrictions related to the COVID-19 pandemic. The meeting focused on advances in: (1) optogenetics as a tool for comprehending neurobiology of diseases and on optogenetically-inspired DBS, (2) cutting edge of emerging DBS technologies, (3) ethical issues affecting DBS research and access to care, (4) neuromodulatory approaches for depression, (5) advancing novel hardware, software and imaging methodologies, (6) use of neurophysiological signals in adaptive neurostimulation, and (7) use of more advanced technologies to improve DBS clinical outcomes. There were 178 attendees who participated in a DBS Think Tank survey, which revealed the expansion of DBS into several indications such as obesity, post-traumatic stress disorder, addiction and Alzheimer’s disease. This proceedings summarizes the advances discussed at the Eighth Annual DBS Think Tank.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

33953663

Language

English

Share

COinS